Abstracts tagged "interferons"

Abstract Number: 692 • 2012 ACR/ARHP Annual Meeting
A Phase 1 Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma
Avram Z. Goldberg¹, Thomas D. Geppert², Elena Schiopu³, Tracy M. Frech⁴, Vivien M. Hsu⁵, Robert W. Simms⁶, Stanford L. Peng⁷, Yihong Yao⁸, Nairouz Elgeioushi⁹, Bing Wang¹⁰, Linda Chang¹¹ and Stephen Yoo¹², ¹Div of Rheumatology, North Shore-LIJ Health System, Lake Success, NY, ²Metroplex Clinical Research Center, LLC, Dallas, TX, ³Rheumatology/Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁵Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷Department of Rheumatology, Benaroya Research Institute at Virginia Mason Medical Center, Seattle, WA, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Medical Biostatistics, MedImmune, Gaithersburg, MD, ¹⁰Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, ¹¹Translational Sciences, MedImmune, Hayward, CA, ¹²Clinical Development, MedImmune, Gaithersburg, MD
Background/Purpose: Type I interferons (IFNs) have been implicated in the pathogenesis of scleroderma. This phase 1 study evaluated safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of…
Abstract Number: 673 • 2012 ACR/ARHP Annual Meeting
Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study
Melissa E. Munroe¹, Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Kathy Moser Sivils⁵, Timothy B. Niewold⁶, Gary S. Gilkeson⁷, Michael H. Weisman⁸, Mariko L. Ishimori⁸, Daniel J. Wallace⁹, David R. Karp¹⁰, John B. Harley¹¹ and Judith A. James¹², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a complex autoimmune disease marked by autoantibody production and immune dysregulation. Identification of at-risk populations is essential to minimize morbidity and mortality…
Abstract Number: 680 • 2012 ACR/ARHP Annual Meeting
Plasma Level of Galectin-3 Binding Protein Reflects Type I Interferon Activity and Is Highly Increased in Patients with Systemic Lupus Erythematosus
Christoffer T. Nielsen¹, Ole Østergaard², Line V. Iversen³, Christian Lood⁴, Anders A. Bengtsson⁴, Anne Voss⁵, Søren Jacobsen⁶ and Niels H. H. Heegaard³, ¹Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ²Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institute, Copenhagen S, Denmark, ³Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁴Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ⁵Dept of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁶Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: Ongoing production of type I interferons (IFN) is a key element in the pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs trigger the…
Abstract Number: 2687 • 2012 ACR/ARHP Annual Meeting
Modular Microarray Analysis Fails to Reveal a Significant Biological Effect of Vitamin D3 Treatment in Patients Participating in a Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Michaela Oswald¹, Cynthia Aranow², Diane L. Kamen³, Meggan C. Mackay⁴, Ellen A. Goldmuntz⁵, Betty Diamond⁶, Peter K. Gregersen⁷ and ALE02 Study Team⁸, ¹Laboratory of Genomics and Human Genetics, The Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institute for Medical Research, Manhasset, NY, ³Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, ⁴Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁵DAIT, NIAID/NIH, Bethesda, MD, ⁶Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, ⁷Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁸NIAID/NIH Rm 6807, Bethesda, MD
Background/Purpose: Vitamin D modulates the immune response. Exposing normal PBMCs to activating SLE sera induces an interferon signature which can be inhibited by preexposure of…
Abstract Number: 2677 • 2012 ACR/ARHP Annual Meeting
IL-23 Controls Autoimmunity by Facilitating Clearance of Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD2 Mice
Hao Li¹, Hui-Chen Hsu², Qi Wu³, PingAr Yang³, Jun Li⁴, Daniel Cua⁵, Mohamed Oukka⁶ and John D. Mountz⁷, ¹Microbiology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Discovery Research, Merck Research Laboratory, Palo Alto, CA, ⁶Pediatrics, Seattle, WA, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Failure to clear apoptotic bodies is a central pathogenic mechanism for SLE. We have observed that spontaneous systemic autoimmunity and lupus in BXD2 mice…
Abstract Number: 2619 • 2012 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus
Cynthia Aranow¹, Maria Dall'era², Elena M. Massarotti³, Meggan C. Mackay⁴, Andreea Coca⁵, Fotios Koumpouras⁶, Marc C. Levesque⁷, W. Winn Chatham⁸, Megan E. B. Clowse⁹, Lisa G. Criscione-Schreiber¹⁰, Sherri Callahan¹¹, Ellen A. Goldmuntz¹², Lynette Keyes-Elstein¹³, Betty Diamond¹⁴ and Diane L. Kamen¹⁵, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁶Lupus Center of Excellence, West Penn Hospital, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Rheumatology, Duke University Medical Center, Durham, NC, ¹⁰Rheumatology, Duke University Health System, Durham, NC, ¹¹Dait, NIAID/NIH Rm 6807, Bethesda, MD, ¹²DAIT, NIAID/NIH, Bethesda, MD, ¹³Rho Federal Systems, Inc., Chapel Hill, NC, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, ¹⁵Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC
Background/Purpose: Exposure of normal PBMCs to1,25 OH vitamin D reverses the stimulatory effects of activating SLE sera on the interferon signature. Given that IFN is…
Abstract Number: 2653 • 2012 ACR/ARHP Annual Meeting
A Subset of up-Regulated IFN Regulated Genes in Candle Patients Decrease with Treatment with a JAK Inhibitor
Adriana Almeida de Jesus¹, Yin Liu², Gina A. Montealegre³, Adam L. Reinhardt⁴, Diane Brown⁵, Antonio Torrelo⁶, Angel V. Casano⁷, Lena Das⁸, Yongqing Chen⁹, Yan Huang⁹, Deborah Stone¹⁰, Dawn C. Chapelle², Nicole Plass², Steven H. Zuckerman¹¹, William Macias¹² and Raphaela T. Goldbach-Mansky², ¹Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ²Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, ³NIAMS, Bethesda, MD, ⁴Rheumatology, Children's Hosp of Omaha/UNMC, Omaha, NE, ⁵Division Of Rheumatology MS #60, Children's Hospital Los Angeles, Los Angeles, CA, ⁶Departments of Pediatric Dermatology, Hospital Niño Jesús, Madrid, Spain, Madrid, Spain, ⁷Meditex Spain, Malaga, Spain, ⁸Pediatric Rheumatology, KK Women's and Children's Hospital, Singapore, Singapore, ⁹Translational Autoinflammatory Disease Section, Office of the Clinical Director NIAMS, Bethesda, MD, ¹⁰National Institute of Arthritis & Muscoloskeletal, National Institutes of Health, Bethesda, MD, ¹¹Immunology, Lilly Research Labs, Indianapolis, IN, ¹²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome is a recently described early-onset autoinflammatory disease caused by autosomal recessive mutations in…
Abstract Number: 2124 • 2012 ACR/ARHP Annual Meeting
Serum Concentrations of Soluble Interferon Receptor in Patients with Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Ryuki Shinohe³, Tsuneo Watanabe² and Katsuji Shimizu³, ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Orthopaedic Surgery, Gifu University, Gifu, Japan
Background/Purpose: Interferon (IFN) exerts antiviral and antineoplastic activities, and is involved in immunoregulatory activities. IFN probably plays an important role in the pathogenesis of rheumatoid…
Abstract Number: 1811 • 2012 ACR/ARHP Annual Meeting
On the Origin of the Type I Interferon Signature in Rheumatoid Arthritis
T.D. de Jong¹, Saskia Vosslamber¹, Maija-Leena Eloranta², Lars Rönnblom², Kyra Gelderman¹, Mary von Blomberg¹, Irene Bultink³, Alexandre Voskuyl⁴ and Cornelis L. Verweij¹, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Presence of a type I interferon (IFN) signature has been described for several autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).…
Abstract Number: 1791 • 2012 ACR/ARHP Annual Meeting
Different Mechanisms Responsible for IVIG Inhibition of Immune Complex Versus TLR Stimulated Interferon-Alpha
Alice Wiedeman¹, Fabian Käsermann², Sylvia Miescher² and Keith B. Elkon³, ¹Department of Immunology, University of Washington, Seattle, WA, ²CSL Behring, Bern, Switzerland, ³Rheumatology Box 356428, University of Washington, Seattle, WA
Background/Purpose: SLE immune complexes (IC) induce IFN-α production by stimulation of TLR7 and 9 in plasmacytoid dendritic cells (pDC). Serum from normal human donors…
Abstract Number: 1440 • 2012 ACR/ARHP Annual Meeting
Lupus-Prone Mice Demonstrate Enhanced Neutrophil Extracellular Trap Formation: Implications for Autoantibody Formation and Organ Damage
Jason S. Knight¹, Alexander A. O'Dell¹, Wenpu Zhao², Ritika Khandpur², Srilakshmi Yalavarthi² and Mariana J. Kaplan³, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Rheumatology, Ann Arbor, MI, ³Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Recent evidence suggests that enhanced neutrophil extracellular trap (NET) formation—the programmed release of chromatin fibers decorated with granular antimicrobial peptides—is as an important activator…
Abstract Number: 1446 • 2012 ACR/ARHP Annual Meeting
The Granulocyte Signature and Organ Inflammation in TLR7 Responsive Mice Is RNA and Type 1 Interferon Dependent
Xizhang Sun¹, Alice Wiedeman², Thomas H. Teal³, Nalini Agrawal³, Jeffrey Duggan², Matt B. Buechler⁴, Jeffrey A. Ledbetter³, Denny Liggitt⁵, Jessica A. Hamerman⁶ and Keith B. Elkon⁷, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, Seattle, ⁵Comparative Medicine, University of Washington, Seattle, WA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Rheumatology Box 356428, University of Washington, Seattle, WA
Background/Purpose: Microarray expression analysis of blood taken from patients with Systemic Lupus Erythematosus (SLE) has revealed two characteristic signatures: one that reflects exposure to type…
Abstract Number: 1067 • 2012 ACR/ARHP Annual Meeting
Spontaneous Aggregation of the Anti-Viral Mavs Protein in Certain Systemic Lupus Erythematosus Patients May Explain Excessive Type I Interferon Production
Philip L. Cohen¹ and Wen-Hai Shao², ¹Rheumatology, Temple University, Philadelphia, PA, ²Medicine, Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Patients with systemic lupus (SLE) often have increased type I interferon levels (IFN-I) and activation of IFN-inducible genes (IFN signature). The mitochondrial adaptor protein…
Abstract Number: 880 • 2012 ACR/ARHP Annual Meeting
Interferon Regulatory Factor 8 Regulates BAFF Production in Murine Macrophages and Is a Nexus for Cross Talk Between IFN-γ and TGF-β
Weijia Yuan¹, Sanjay Gupta², Jane E. Salmon³ and Alessandra B. Pernis², ¹Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ²Autoimmunity & Inflammation, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ³Dept of Medicine, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Lupus is a systemic autoimmune disease that can lead to severe end-organ damage characterized by unabated inflammation and aberrant tissue repair. Macrophage dysregulation plays…
Abstract Number: 885 • 2012 ACR/ARHP Annual Meeting
Interferon α and Self-Organized Criticality Theory
Shunichi Shiozawa¹, Yumi Miyazaki² and Ken Tsumiyama³, ¹Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ²Kyushu University Beppu Hospital/ Kobe University Graduate School of Health Sciences, Beppu/ Kobe, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: One of the biggest obstacle we face in elucidating the pathogenesis of autoimmunity today is the mechanism how autoreactive lymphocyte clones could survive or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].